Brief: Galmed Announces New Positive Data From Ongoing Study Open Label Part Showing Clinically Significant Effect On Fibrosis Improvement
08/11/2021 12:17
Nov 8 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O :
* GALMED ANNOUNCES NEW POSITIVE DATA FROM ONGOING ARMOR
STUDY OPEN
LABEL PART SHOWING CLINICALLY SIGNIFICANT EFFECT ON FIBROSIS
IMPROVEMENT
* GALMED - STATISTICALLY SIGNIFICANT REDUCTIONS IN
BIOMARKERS
ASSOCIATED WITH LIVER FIBROSIS INCLUDING ALT, AST, FIB-4 AND
PROC-3 WAS ALSO OBSERVED
Source text for Eikon: ID:nPn79dZsZa
Further company coverage: GLMD.O
((Reuters.Briefs@thomsonreuters.com;;))